Dyax Announces Final Patient Treated in Pivotal Phase III Clinical Trial (EDEMA3) for DX-88 in Hereditary Angioedema
23-Nov-2006 -
Dyax Corp. announced that it has completed the double-blind portion of its pivotal Phase III clinical trial, known as EDEMA3, for its lead product candidate DX-88 (ecallantide) for the treatment of hereditary angioedema (HAE). In addition, the U.S. Food and Drug Administration has also broadened ...
clinical trials
dosing
food
+1